K
Keros Therapeutics Inc (KROS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$10.03
-0.27 (-2.62%)
Market Cap: $202.13M
Last updated: Nov 17, 2026 at 11:05 AM ET
Keros Therapeutics Inc (KROS) Valuation Multiples
Keros Therapeutics (KROS) trades at 4.9x sales and 0.7x book value. Its P/B of 0.7x is below its 5-year median of 3.6x. Its forward P/E is 48.8x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 48.8x |
| Price to sales | 4.9x |
| Price to book | 0.7x |
| EV/FCF | 1.2x |
| PEG | N/A |
| FCF yield | -24.2% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 0.7x | 3.6x | N/A |
Valuation History
Over the 3 of the 6 year ends shown that have a P/S, its P/S ranged from 3.4x in 2025 to 177.7x in 2024.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $20.36 | 11.2x | 3.4x | 2.5x |
| 2024 | $15.83 | N/A | 177.7x | 1.1x |
| 2023 | $39.76 | N/A | N/A | 3.6x |
| 2022 | $48.02 | N/A | N/A | 4.7x |
| 2021 | $58.51 | N/A | 68.2x | 5.6x |
| 2020 | $70.54 | N/A | N/A | 5.8x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About KROS
What is KROS's forward P/E ratio?
Keros Therapeutics has a forward P/E ratio of 48.8x.
Is KROS stock overvalued?
GNG's valuation label for KROS is Undervalued.
What is KROS's price to sales ratio?
Keros Therapeutics has a price to sales ratio of 4.9x.
KROS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors